Nicholas Hoffman & Company LLC. Buys 215 Shares of Medtronic PLC (MDT)
Nicholas Hoffman & Company LLC. raised its holdings in shares of Medtronic PLC (NYSE:MDT) by 1.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,837 shares of the medical technology company’s stock after buying an additional 215 shares during the period. Nicholas Hoffman & Company LLC.’s holdings in Medtronic PLC were worth $1,228,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Captrust Financial Advisors purchased a new stake in shares of Medtronic PLC during the second quarter valued at $384,000. Wesbanco Bank Inc. raised its holdings in Medtronic PLC by 3.1% in the 2nd quarter. Wesbanco Bank Inc. now owns 10,170 shares of the medical technology company’s stock valued at $903,000 after acquiring an additional 308 shares during the last quarter. Dupont Capital Management Corp raised its holdings in Medtronic PLC by 28.8% in the 2nd quarter. Dupont Capital Management Corp now owns 74,052 shares of the medical technology company’s stock valued at $6,572,000 after acquiring an additional 16,562 shares during the last quarter. Chilton Investment Co. LLC raised its holdings in Medtronic PLC by 6.1% in the 2nd quarter. Chilton Investment Co. LLC now owns 26,842 shares of the medical technology company’s stock valued at $2,382,000 after acquiring an additional 1,538 shares during the last quarter. Finally, RMB Capital Management LLC purchased a new stake in shares of Medtronic PLC in the 1st quarter valued at approximately $4,576,000. 81.37% of the stock is owned by hedge funds and other institutional investors.
A number of equities research analysts have issued reports on the stock. Oppenheimer Holdings, Inc. reiterated a “buy” rating and set a $92.00 target price on shares of Medtronic PLC in a report on Tuesday, August 22nd. Jefferies Group LLC reiterated a “buy” rating and set a $103.00 price target on shares of Medtronic PLC in a research note on Thursday, August 3rd. BMO Capital Markets reissued an “outperform” rating and set a $89.00 price objective (down from $92.00) on shares of Medtronic PLC in a research report on Tuesday, October 10th. SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $96.00 target price on shares of Medtronic PLC in a report on Friday, November 3rd. Finally, BidaskClub downgraded shares of Medtronic PLC from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and thirteen have issued a buy rating to the stock. Medtronic PLC has a consensus rating of “Hold” and a consensus target price of $87.88.
In related news, CEO Omar Ishrak sold 140,407 shares of Medtronic PLC stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $81.63, for a total transaction of $11,461,423.41. Following the transaction, the chief executive officer now owns 668,503 shares of the company’s stock, valued at $54,569,899.89. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Bryan C. Hanson sold 16,000 shares of Medtronic PLC stock in a transaction on Monday, October 16th. The stock was sold at an average price of $78.03, for a total value of $1,248,480.00. The disclosure for this sale can be found here. 0.31% of the stock is owned by company insiders.
Shares of Medtronic PLC (MDT) opened at $79.16 on Wednesday. Medtronic PLC has a 12 month low of $69.35 and a 12 month high of $89.72. The company has a quick ratio of 1.40, a current ratio of 1.64 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $107,283.60, a price-to-earnings ratio of 16.89, a P/E/G ratio of 2.15 and a beta of 1.00.
Medtronic PLC (NYSE:MDT) last released its earnings results on Tuesday, August 22nd. The medical technology company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.04. Medtronic PLC had a return on equity of 12.92% and a net margin of 13.75%. The company had revenue of $7.39 billion for the quarter, compared to analyst estimates of $7.44 billion. During the same period in the prior year, the firm posted $1.03 EPS. Medtronic PLC’s quarterly revenue was up 3.1% on a year-over-year basis. equities analysts expect that Medtronic PLC will post 4.7 earnings per share for the current year.
The company also recently announced a quarterly dividend, which was paid on Friday, October 20th. Shareholders of record on Friday, September 29th were given a $0.46 dividend. The ex-dividend date of this dividend was Thursday, September 28th. This represents a $1.84 annualized dividend and a yield of 2.32%. Medtronic PLC’s dividend payout ratio is presently 61.95%.
Medtronic PLC Profile
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT).
Receive News & Stock Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related stocks with our FREE daily email newsletter.